Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.
about
Functional neuroimaging in Parkinson's diseaseSurrogate outcomes in neurology, psychiatry, and psychopharmacology[123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly.In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriersMultiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathiesThe patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's diseaseNeuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease.[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's diseaseDisease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulationPremotor Parkinson's disease: concepts and definitionsManganese: recent advances in understanding its transport and neurotoxicityNeurodegeneration and neuroprotection in Parkinson disease.PET 6-[F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates.Molecular imaging as a guide for the treatment of central nervous system disordersCognitive impairment and dementia in patients with Parkinson disease.Milestones in neuroimaging.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Functional neuroimaging in Parkinson's disease.Position Emission Tomography/Single-Photon Emission Tomography Neuroimaging for Detection of Premotor Parkinson's Disease.Transcranial sonography of the substantia nigra: digital image analysis.Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case-control study in Japan.Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease.Substantia nigra hyperechogenicity in healthy controls: a [¹⁸Fluoro] Dopa-PET follow-up study.[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism.Potential impact of self-perceived prodromal symptoms on the early diagnosis of Parkinson's disease.123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder.Validation of the three-dimensional acquisition mode in positron emission tomography for the quantitation of [18F]fluoro-DOPA uptake in the human striata.On the rate of decarboxylation of dopa to dopamine in living mammalian brain.Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson's Disease.Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.Neuroimaging in Parkinson's disease
P2860
Q27013767-485836F5-C2BD-4C4A-9051-9C9AD3650D84Q30473416-9FBA7F30-CF59-4335-B450-6237A5355884Q32052220-9CBAEBBA-C6F1-4A9D-B2B1-CB36CA74A109Q33632441-E23FAF6C-2436-4D15-A9BE-DE9B6846B0C3Q34071200-8CDC519E-8066-48C2-90CB-0A822F080A5AQ34078528-231DF3F1-0260-41EE-BCEF-3D4419E62E53Q35089830-8BCD9918-BD8B-4A9D-A90F-F58CA0709A4AQ35452760-67006E86-C6D0-4677-A5E0-F9D33385533EQ35471953-DC5CD83E-9012-47CB-8503-0B23043A85C4Q35490116-24757B5C-647E-4F7A-BBCA-8DF5D1A90F29Q35910731-1459E20F-F6B4-4949-ABF7-D67C55F96959Q35946187-23528046-994E-43C0-9357-448F52E1059EQ36045259-A0FB1056-3455-4118-B4C5-7AD9ECD5060BQ36852867-E7B5730D-AA8E-42A8-8D11-D3A842D2E454Q37262953-0540D844-32E0-40AB-B1D3-7C64C284B731Q37597279-772B8D31-FC7C-4E92-82DA-2FE86CEF7A0CQ37882576-997FF478-A881-48FB-BEF4-2D750991AEA8Q37979869-68067EBC-5F8F-4FC1-A124-B6687C103960Q38088371-952A095A-CBE9-4578-B0D7-CD09A268BBA2Q38699508-27285C88-CFB2-487D-A6D2-1374E87DBB87Q40210090-5B123B35-4C74-4271-AC93-ABA95AA1BBD8Q41743797-EA8BF9C6-0859-4F24-9DAF-D0290566B599Q41953550-B8DB74F1-2EBB-437E-B5C3-60483B3393D7Q42164079-11056D2B-55E4-46EA-B4D0-39FCEEAB73F0Q43118698-BB298435-C39D-47BD-89D6-43B055241987Q43693338-71AA3601-F4BE-4306-B68C-7C1A43713D71Q43708045-F7D32FCF-9D9C-4A5F-BC0F-356578C71384Q43959453-88C7768A-BDCA-4F94-9AC2-18B8678D28F2Q44125051-6CBF3D2C-B9BD-41A9-AFB2-E8CED870D558Q45337355-A1988FE5-87BC-478C-AC4B-0825F4C4A78FQ48011827-71DD8FCF-7371-4BC6-8FD4-F606375BEFB8Q48245989-4A26F7A6-1EF5-4762-AA1C-3966AB398332Q48394540-99FEE82F-97AC-4856-ABF7-C34CB754F339Q48455026-85C24C68-6E1F-42BB-A39D-876CF8B9BA5CQ49834489-657B8A07-6E1F-4708-BE9E-994E0D419262Q51372615-8E1A3078-16C3-4442-A55A-02C888280194Q57088961-A902A6DA-4F10-4C85-BA33-D2B964E63673
P2860
Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Longitudinal fluorodopa positr ...... on of idiopathic parkinsonism.
@en
Longitudinal fluorodopa positr ...... on of idiopathic parkinsonism.
@nl
type
label
Longitudinal fluorodopa positr ...... on of idiopathic parkinsonism.
@en
Longitudinal fluorodopa positr ...... on of idiopathic parkinsonism.
@nl
prefLabel
Longitudinal fluorodopa positr ...... on of idiopathic parkinsonism.
@en
Longitudinal fluorodopa positr ...... on of idiopathic parkinsonism.
@nl
P2093
P2860
P356
P1433
P1476
Longitudinal fluorodopa positr ...... on of idiopathic parkinsonism.
@en
P2093
P2860
P304
P356
10.1002/ANA.410360512
P577
1994-11-01T00:00:00Z